Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript

Absci Corporation (NASDAQ:ABSI) Q1 2025 Earnings Call Transcript May 13, 2025

Absci Corporation beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.23.

Operator: Thank you for standing by, and welcome to Absci’s First Quarter 2025 Business Update and Financial and Operating Results Conference Call. At this time all participants are in a listen-only-mode. After the speaker presentation there will be a question-and-answer session. [Operator Instructions] I would now like to hand the call over to Alex Khan, VP, Finance and Investor Relations. Please go ahead.

Alex Khan: Thank you. Earlier today, Absci released financial and operating results for the quarter ended March 31, 2025. If you haven’t received this news release or if you would like to be added to the company’s distribution list, please send an e-mail to investors@absaci.com. An archived webcast of this call will be available for replay on Absci’s Investor Relations website at investors.absci.com for at least 90 days after this call. Joining me today are Sean McClain, Absci’s Founder and CEO; and Zach Jonasson, Chief Financial Officer and Chief Business Officer. Christian Stegmann, Absci’s SVP of Drug Creation, will also join for Q&A following prepared remarks. Before we begin, I’d like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws.

These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the section titled Forward-Looking Statements in the press release Absci issued today and the documents and reports filed by Absci from time to time with the Securities and Exchange Commission. Except as required by law, Absci disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, either because of new information, future events or otherwise.

This conference call contains time-sensitive information and is accurate only as of the live broadcast, May 13, 2025. With that, I’ll turn the call over to Sean.

Sean McClain: Good afternoon, everyone. Thank you for joining our Q1 2025 business update call. Today marks a significant milestone for Absci. We have initiated our first-in-human clinical trial for ABS-101, officially making Absci a clinical stage biotech company. It’s incredible to see how far we’ve come in just a short time. About 2.5 years ago, Andreas Busch, an experienced drug hunter, joined Absci as our Chief Innovation Officer. Under Andreas’ leadership and with the talented team he assembled, we quickly leveraged our AI platform to create a robust pipeline of potential best-in-class and first-in-class therapeutics. Today, I’m proud to announce the start of our Phase I clinical trial for ABS-101, our potential best-in-class anti-TL1A antibody.

This randomized, double-blind, placebo-controlled trial of single ascending doses of ABS-101 will evaluate its safety, tolerability, pharmacokinetics and pharmacodynamics in approximately 40 healthy adult volunteers. The primary focus is safety and tolerability with PK, PD and immunogenicity as secondary endpoints. We expect interim results later this year from this ongoing study in Australia. As a reminder, ABS-101 is a potential best-in-class TL1A antibody, demonstrating high affinity, potency, ability to bind both TL1A monomer and trimer, anticipated low immunogenicity and high bioavailability shown in nonhuman primates. Additionally, it’s formulated for convenient sub-Q administration with an anticipated dosing interval of 8 to 12 weeks.

Recent data indicates ADS-101 may have a lower chance of developing antidrug antibodies in clinical settings compared to a competitor molecule with high clinical ADA rate. Our recent NHP studies confirm prolonged dose-dependent target engagement with a clear ceiling effect, and ADS-101 was well tolerated in a 13-week GLP study in NHP. Interest from potential partners remains high for this program. Additionally, we are progressing on a bispecific program with a novel arm in conjunction with our TL1A antibody. We’ll share more details on this program at a later date for competitive reasons. ABS-101 exemplifies the power of our generative AI platform, demonstrating our capability to rapidly engineer therapeutics with precision. With a growing pipeline of AI-designed antibodies, we’re accelerating our mission of bringing better biologics to patients faster.

Turning to ABS-201, our potential groundbreaking anti-prolactin receptor antibody for androgenic alopecia, commonly known as male and female pattern hair loss. This condition affects approximately 80 million adults in the U.S. alone and hasn’t seen significant therapeutic innovation in nearly 30 years. ABS-201 represents a potential new category of therapy, offering durable effective hair regrowth. We recently nominated a development candidate with strong preclinical evidence that we believe supports high potency, favorable safety, low immunogenicity, extended half-life and manufacturability. We believe ABS-201 could offer significant improvements over current standard of care treatments, like finasteride and minoxidil, known for their side effects and variable or limited efficacy.

We have previously shown in preclinical models that ABS-201 outperformed moninoxadil in hair regrowth. Today, we’re pleased to share results from our recent NHP study confirming ABS-201’s extended half-life and potential to translate into a dosing interval of every 8 to 12 weeks in humans. The data also indicates excellent subcutaneous bioavailability of greater than 90% in NHPs. The observed PK profile is projected to result in substantial exposure in skin and hair follicles at clinically relevant doses. We believe ABS-201 also supports high concentration formulation potential of greater than 150 mg per ml, facilitating patient convenience. We’re advancing rapidly towards the clinic with guidance from a network of leading hair and dermatology experts.

ABS-201 continues IND-enabling studies with a Phase I trial expected in early 2026 and interim efficacy data anticipated later that year. Given its potentially promising profile, defined development path and large market, we plan to develop ABS-201 internally through later-stage clinical development and proof of concept to retain maximum value. We’re also progressing on two other additional programs. ABS-301, a potential first-in-class antibody targeting an undisclosed immuno-oncology target identified through our reverse immunology platform. Early data indicate potential broad applicability to squamous cell carcinomas and other indications. ABS-501, a potential best-in-class anti-HER2 antibody identified using our zero-shot de novo AI models.

These AI designed leads display novel epitope interactions, increased or equivalent affinity to trastuzumab in preclinical settings, efficacy against trastuzumab-resistant xenograft tumor expressing wild-type HER2 and good developability Innovation is at the core of Absci’s success, and we must constantly strive for improvement. Recent initiatives like the National Security Commission on Emerging Biotechnology report support U.S. leadership in biotech, aligning closely with our mission. A topic I spoke passionately about at the 2023 U.S. Senate AI Forum on innovation. We were also encouraged by the FDA’s recent proposal to reduce or eliminate certain animal tests for monoclonal antibodies, favoring advanced technologies like AI and biosimulation models.

This road map fits squarely with our approach of using AI models to design and optimize antibodies for safety, specificity and efficacy. For example, our AI models for naturalness introduced in our 2022 manuscript evaluates how closely an antibody resembles the natural immune repertoire and mitigates potential downstream developability and immunogenicity issues by prioritizing more natural antibody variants. As a leader in AI drug discovery, we are encouraged by this recent announcement from the FDA and look forward to next steps. In conclusion, Absci remains committed to leading biotech innovation, harnessing AI to deliver life-changing treatments. Thank you to our talented team, the dedicated Unlimiters at Absci, whose hard work and dedication drive our mission each and every day.

With that, I’ll now turn the call over to Zach to walk through our partnerships, our outlook and provide an update on our financials. Zach?

Zach Jonasson: Thanks, Sean. As Sean mentioned, we continue to execute across all aspects of our business. This includes progressing our internal and partner programs, as well as advancing discussions with prospective new high-quality partners. As our business development discussions remain robust, we continue to anticipate signing one or more drug creation partnerships, including with a large pharma company this year. We also plan to continue providing material updates when possible about ongoing internal and partnered programs as they advance through development. As we think about the growing capabilities of our AI platform, we believe our greatest value proposition is designing novel and differentiated therapeutic assets that address unmet medical needs.

Accordingly, in addition to leveraging our platform to reduce drug design time lines and costs, we are increasingly focused on applying the platform design therapeutics addressing disease targets for which legacy drug discovery approaches have been unsuccessful. The HIV Caldera case study, which we have shared previously, as well as recent successes in several of our partnerships give us confidence in our ability to design therapeutics addressing challenging target classes, both in our own internal programs and in our partnerships. We are pleased to note a growing number of discussions with industry participants who recognize the potential unique value we can bring to drug creation collaborations. As Sean discussed earlier, we recently achieved a key milestone in our evolution as we officially became a clinical stage biotech with ABS-101 entering the clinic.

We are also excited to see ABS-201, our hair regrowth program, accelerating toward the clinic as we anticipate initiation of a first-in-human trial in early 2026. As a reminder, our business model is focused on out-licensing or selling our internal programs and co-developed programs following value inflection proof points. These potential transactions could occur as early as preclinical proof of concept or at much later stages. Along those lines, we continue to be engaged with multiple interested parties regarding a potential transaction for our ABS-101 TL1A program. Meanwhile, as Sean mentioned earlier, we see strong rationale to retain and develop our ABS-201 androgenic alopecia program through much later stages of development. This program offers a straightforward clinical development pathway, which includes objective endpoints and the potential for rapid clinical trial recruitment, as well as the potential to achieve a proof of concept in our Phase I trial design.

Turning now to our financials. Revenue in the first quarter was $1.2 million as we continue to progress our partner programs. Research and development expenses were $16.4 million for the 3 months ended March 31, 2025, as compared to $12.2 million for the prior year period. This increase was primarily driven by advancement of our internal programs, including direct costs associated with external preclinical development and an increase in personnel and stock compensation expense. Selling, general and administrative expenses were $9.5 million for the 3 months ended March 31, 2025, as compared to $8.7 million for the prior year period. This increase was due to an increase in stock compensation expense. Turning to our balance sheet. We ended the quarter with $134 million in cash, cash equivalents and short-term investments as compared to $112.4 million as of December 31, 2024.

With this strong balance sheet and line of sight to multiple potential catalysts in the near term, we will continue to invest in our internal program portfolio, including supporting the acceleration of development for ABS-201 androgenic alopecia program and ensure that we maintain a strong healthy capital position while executing on the strategy. Overall, we continue to deepen our focus on high-value proprietary internal programs, while also seeking high-quality co-development and drug creation partnerships with industry leaders who bring synergistic expertise and technology. We believe that this strategy and balanced approach will provide the best return for our shareholders. Based on our current plan, we believe our existing cash, cash equivalents and short-term investments will be sufficient to fund our operations into the first half of 2027.

And as a reminder, we see additional upside to this forecast through nondilutive cash inflows, which could come from potential new platform collaborations with large pharma and/or an asset transaction around any of our wholly owned programs, such as our ABS-101 TL1A asset. In sum, we are very pleased with our recent progress and are confident in our ability to execute across our portfolio of programs this year and beyond. With that, I’ll turn it back to Sean.

Sean McClain: Thanks, Zach. Today is a deeply gratifying day, not just for me as a founder, but for all of Absci and the dedicated Unlimiters who bring our mission to life. 14 years ago, when we started this journey, we knew nothing would come easy. From the beginning, we’ve relied on drive, tenacity, innovation and perseverance, not just to survive, but to thrive in the face of uncertainty. As we complete our transition to a clinical stage company, I think back to those early days in the basement lab, our mission hasn’t changed to harness technology and science to improve the lives of patients everywhere. And today, I’m proud to see our continued execution bring us closer to that goal. Looking ahead, ABS-101 is now in the clinic, and we expect to share interim data in the second half of this year.

ABS-201, our hair regrowth program, is also gaining momentum as it moves towards the clinic. We plan to begin first-in-human studies in early 2026 with an interim efficacy readout expected later that year. Beyond our internal programs, and as Zach mentioned, we have a clear line of sight to bring one or more new large pharma partners into our growing ecosystem of collaborators this year. None of this would be possible without the incredible work of our Unlimiters. To everyone at Absci, thank you for your continued dedication to our mission. With that, I’ll turn the call back over to our operator to begin Q&A. Operator?

Q&A Session

Operator: Thank you. [Operator Instructions] Our first question comes from the line of Arseniy Shabashvili of Guggenheim Securities. Please go ahead, Arseniy.

Arseniy Shabashvili: Hi. This is Arseniy on for Vamil. Thank you for taking our questions. And congrats on all your progress. Regarding ABS-101, what are you hoping to see in the Phase I top line in the second half of the year in terms of PK and immunogenicity endpoints, as well as any other metrics you may be looking at?

Sean McClain: Yes. Thanks, Arseniy. First off, we’re looking to see a really nice safety profile looking at immunogenicity. The second is looking at target engagement. We’re hoping to see similar target engagement data as what we saw and presented at the JPMorgan Healthcare Conference earlier this year. And Christian, is there anything else that you’d like to add in terms of what we’d like to see for ABS-101?

Christian Stegmann: Yes, absolutely. We would like to – in addition to what Sean mentioned, we would like to validate the extended half-life to really demonstrate that in humans, we can potentially support dosing of every 2 months to every 12 weeks. And then as Sean mentioned, we will continue to observe and hopefully validate expected low immunogenicity, and overall good tolerability and safety profile and then demonstrate target engagement as measured by the elevation of total soluble TL1A. And note that the elevation of total soluble TL1A will also be measured over an extended period of time, really then demonstrating not only an extended half-life in terms of the PK of the antibody, but also the pharmacodynamics, meaning we see an elevation of total soluble TL1A in – over an extended period of time, really demonstrating target engagement and confirming the overall target product profile.

Arseniy Shabashvili: Thank you. And one more, if I may, regarding 201. Obviously, it is the early days, but based on what you now know, do you think this product can potentially be self-administered in the future?

Sean McClain: Yes. We do believe this can be self-administered. Right now, though, we are working – we want to work with dermatologists on being able to make sure that this is effectively administered. And so we do think, over time, it could be self-administered, but we do think working with the providers initially is likely the best route to go.

Arseniy Shabashvili: Thank you.

Operator: Our next question comes from the line of Brendan Smith of TD Cowen. Please go ahead, Brendan.

Brendan Smith: Great. Thanks for taking my questions, guys. Congrats on all the progress. Maybe just a quick one from us on 201. As you look at the data today and think about a potential clinical trial ahead, I guess, how are you thinking about potential market segmentation here? And I guess maybe just among that 80 million to 90 million patient figure that I think you flagged in the past, I guess, who among them do you think would maybe be lowest hanging fruit to target first and just kind of how you’re thinking about that rollout?

Sean McClain: Zach and Christian, do you want to take that?

Zach Jonasson: Yes. This is Zach. I’d be happy to. It’s a great question, Ben. We spent a lot of time with our KOL network evaluating that. At this point, we think this mechanism could be efficacious in almost all of those segments for androgenic alopecia. So we are looking at a Phase I trial design where we’ll see some breadth in terms of age, both male and female. We’ll put out more data around that trial design later this year. But as of today, just looking at the mechanism and the strong translational data, including the human genetics that support safety, we don’t see any particular segment of that population that could not be treated, but it’s certainly something we’re going to have to evaluate in the human clinical trial setting. And Christian, I don’t know if you want to add anything?

Christian Stegmann: Yes. Great point, Zach. Not much to add. As you correctly pointed out, we will observe as we go into clinical development, how this product is best administered, how it is best served in different populations. And I think this will inform our commercialization strategy. I will flag that beyond androgenic alopecia, there is potential for this mechanism as well. So beyond the market segmentation in androgenic alopecia, it will also be interesting to look in indications such as endometriosis where this mechanism has a potential, and we are actively exploring that as well.

Brendan Smith: Got it. Okay, great. Thanks, guys.

Operator: Our next question comes from the line of Gil Blum of Needham & Company. Please go ahead, Gil.

Gil Blum: Good afternoon, everyone and allow me to add my congrats to the progress here. So maybe a couple of questions on 201. Now that we have some pharmacokinetics from the nonhuman primate model, maybe kind of initial thoughts on the type of dosing you’re going to first look at in humans? And kind of as a follow-on, so I remember the idea was to inject the compound to the target site. How much systemic exposure did you observe in the NHP model? Thank you.

Sean McClain: Christian, do you want to take that?

Christian Stegmann: Yes. So we will disclose the full pharmacokinetic data set at a later point in time at a scientific venue. I will say that we have as we’ve shown, a very attractive pharmacokinetic profile in nonhuman primates. We think it is conducive based on the pharmacokinetic, pharmacodynamic modeling we’ve done to a dosing of every 8 to 12 weeks, as Sean mentioned earlier. We think this is overall a very attractive profile, in particular, for an aesthetic indication as androgenic alopecia. And we anticipate that this product will be dosed every – over a 6-month treatment period. So you could imagine that we can achieve this treatment regimen in just 2 or 3 doses. So we think that’s attractive. And with regards to the total exposure, stay tuned. We will disclose the full data at a scientific venue at a later point in time. Does that answer your question?

Operator: Thank you. Our next question comes from the line of Vikram Purohit of Morgan Stanley. Please go ahead, Vikram.

Unidentified Analyst: Hi, everyone. This is Morgan on for Vikram. Thanks for taking our question. And again, I wanted to extend our congratulations on all the progress this quarter. I wanted to ask a quick question on ABS-301 and when we can expect that development candidate to be shared? Thank you so much.

Sean McClain: Thanks, Morgan. We are continuing to advance it. We recently showed some recent target validation data last quarter, and we are still progressing towards a DC. We have not disclosed at this point in time when that DC will be ready, but we are doing in vivo validation or in vivo studies currently and after that, should be ready to nominate a drug candidate.

Unidentified Analyst: Okay. Appreciate it. And then one last question on ABS-201 for that interim data readout, I know it’s still very early days, but do you have a sense of what kind of data will be shared there and what could be expected based on what you’re seeing right now?

Sean McClain: Yes. We are looking to have that be an interim proof-of-concept readout from both – potentially both from the SAD portion as well as the MAD portion of that study, which would be in the second half of this year. And as we get closer to that study, we will be disclosing more of the study design of that. But again, we do expect a potential efficacy readout in the second half of next year on that trial.

Unidentified Analyst: Excellent. Thank you very much.

Operator: Thank you. Our next question comes from the line of George Farmer of Scotiabank. You question please, George.

George Farmer: Hi, good afternoon. Thanks for taking my question. Sean, can you elaborate a little bit more on this combo strategy that you have with 101? That sounds pretty intriguing. And regarding the partnership that you have with AstraZeneca, I recall that there was a big milestone that you guys had hit with them. Can you give us an indication of like whether you may be getting any milestones in the near future, maybe just on a qualitative basis, how substantial those could be? And then number three, regarding 501, how do you see this drug fitting into the competitive landscape? It’s a pretty crowded area. And how is this really differentiated? Thanks.

Sean McClain: Yes. So first off, on the combo, what we’re seeing, especially as we’re engaging with large pharma on this. There is a push into combo-based approaches. You’re seeing J&J really lead the way on this. And you’re starting to see also combo-based approaches coming from AbbVie as well. And so we do think that a TL1A combo-based strategy is likely to help increase overall efficacy and durability. And that’s a direction that potential partners are thinking of with regards to ABS-101. And then we also have a bispecific strategy with a novel arm, so BTL1A with a novel arm. And this is not the typical IL-23 or alpha4beta7 arm. This is a novel target we are pursuing with that bispecific strategy. And I’ll let Zach take the AZ question, and then Christian can take 501.

Zach Jonasson: George, it’s Zach. Unfortunately, we can’t give any specific commentary around any of those partnerships. As you’ll appreciate, they’re all under NDA provisions. I can share like more generally, I think we’ve mentioned publicly about some more recent successes in some of our other partnerships, including applying our platform to develop antibodies that actually effectively block an ion channel. That’s been one of these targets that’s been very challenging to address. So I can make some general comments like that, but I can’t give you anything specific.

Christian Stegmann: This is Christian. Answering your question on ABS501. Yes, obviously, you’re correct. The HER2 space is indeed a very competitive space. We have currently ongoing a number of preclinical studies that will help us to position ABS501 in this space. Among them could also be combination approaches, and we are exploring actively where that potential niche is. These studies are currently ongoing. We may have a drug candidate this year, but potentially also next year depending on the timing of the studies and the data as they emerge.

George Farmer: Okay. And Sean, again, back to the combo approach. This bispecific that you’re referring to, is this one of an in-house bispecific that you’re making? Or is it somebody else’s?

Sean McClain: This is an in-house bispecific that we have developed. And so we’re — in addition to that bispecific, we’re also developing the other arm of this novel target as well as a mono-based therapy. But this is all developed in-house.

George Farmer: Okay. Thanks.

Operator: Thank you. Our next question comes from the line of Kripa Devarakonda of Truist Securities. Please go ahead, Kripa.

Unidentified Analyst: This is Alex on for Kripa. First, congrats on the progress and becoming commercial stage. That’s fantastic. And a question from our side. As the assets continue in development, ABS-101 and ABS-202, as they progress, is there also an updated sentiment on how you think about future partnerships? Namely, do you think you can command improved economics? Is there any change to that? Or any key differences that you see how your business might evolve given the success in the clinic? And then another one from us on your cost structure. Could you speak to how flexible it is with fixed and variable costs? And namely, as many people are concerned about the state of the markets, biotech markets specifically at the moment, are you able to run any more leanly if you need to? Thanks.

Sean McClain: Yes. Thanks, Alex. I’ll let Zach take both those questions.

Zach Jonasson: Hey, Alex, great questions. In terms of the platform and the kind of deal terms that we think we’ll see in the future and going forward, I would answer your question by saying, yes, but due to two reasons, I mean, we do hope to see enhanced deal terms, certainly with some success with ABS-101 and that interim data readout. I think that’s an important milestone for the company and helps provide additional validation of the platform. But the other really exciting developments on the platform is that now that we’re in version 3 of our models moving into version 4, we’ve shown an ability to address these very challenging target classes. And as an example of that is the HIV Caldera case study that we’ve put out publicly at the end of last year.

But also more recently, some successes in various partnerships that we have ongoing. And so we feel like that is a really significant value proposition that differentiates us from many other players really in the field. And so we’re seeing a lot of engagement from pharma around how they could potentially leverage our platform to address some of these targets that they struggled with. So we’re looking forward to advancing these discussions and negotiations over the next year to see what kind of terms we can reach on drug creation partnerships. But we do expect to see them increase materially versus what we’ve done in prior years. And then on your question pertaining to cost structure, I would say we continually look for ways to leverage more efficiencies out of the AI platform.

And I just mentioned we’ve made some advances there, and we continue to make advances year-on-year really on a quarterly basis with the platform. So we do see opportunities to reallocate resourcing and also to reduce certain areas of resourcing as we leverage more and more of our AI capability. And that’s – for Absci, that’s an ongoing process that we evaluate each and every quarter.

Unidentified Analyst: Thank you.

Operator: Thank you. Our next question comes from the line of Debanjana Chatterjee of Jones. Your question, please, Debanjana.

Debanjana Chatterjee: Hi. Thanks for taking my questions. So I have two. The first one is that assuming that you see optimal results as you expect in the Phase I readout for ABS-101, as you think about the Phase II, will the study include both open-label and randomized arms similar to the design in one of the competitor trials?

Sean McClain: Thanks. That’s a great question. At this time, we have not disclosed what the Phase Ib/IIa is going to look like. As the interim data comes out, we’ll be sharing more information on what those studies are going to be looking like in the future.

Debanjana Chatterjee: Okay. Great. And one follow-up. So this is broader. As the FDA shifts towards minimizing animal use for safety testing and emphasizes AI-based safety predictions, can you leverage Absci’s data first AI-driven platform to model toxicity and predict safety? And is Absci better positioned than its non-AI-driven peers to navigate this shift?

Sean McClain: Yes, absolutely. We’re really excited to see the FDA wanting to leverage AI models to help reduce toxicity and immunogenicity. And as we mentioned on the call, one of the models that we’ve developed that we released in 2022 was our naturalness model and being able to ensure that the antibodies are as human-like as possible. And we see this as a big advantage for us moving forward, in particular, in being able to reduce overall immunogenicity and ensure favorable developability and manufacturability, but also helping to align with the FDA on where they’re going. And so we see this definitely as a big advantage for us moving forward. And Christian, please added anything else.

Christian Stegmann: Yes, very well said, Sean. Indeed, I think the developments at the administration are very exciting for us. We will continue to engage and continue to follow the FDA’s process and advisory relationships to observe what the next steps are. These things will usually also result in revised globally harmonized guidelines. And this is indeed a very exciting opportunity as these efforts towards reducing usage of animals are taking – these measures are taking place, we will see a much more broad adoption of AI models. And clearly, this is a very interesting opportunity for Absci.

Debanjana Chatterjee: Okay. That’s very helpful;. Thank you.

Operator: Thank you. [Operator Instructions] Our next question comes from the line of Li Chen of H.C. Wainwright. Your question please, Lee.

Li Chen: Hello. Hello, everyone. Congratulations on the quarter. So to expand on the TL1A questions a little bit. So can you give us some understanding of the strategy behind going after the novel target of the bispecific instead of your competitor strategy of going for the clinical approved targets? So what’s the advantage of this novel target?

Sean McClain: Yes. Thank you, Li Chen. So this is a known target with known biology. It’s been difficult to drug both from an antibody standpoint as well as a small molecule. And we have figured out a way to drug it with an antibody. And we do think that it has really strong synergy with our TL1A asset. And I’ll hand it over to Christian to maybe go in a little bit more depth on some of the biology.

Christian Stegmann: Yes, 100%. So this target, we have – as Sean mentioned, we have not disclosed this target. So we have to tread a little bit lightly in terms of what I can tell you in terms of the details here. But what I can say is that just like TL1A, the mechanism is a pro-inflammatory mechanism that is clinically highly relevant in autoimmune diseases. Hence, we believe there is a very good rationale for combining it with an anti-TL1A antibody. As Sean mentioned, we are actively working on a bispecific on this combination. And we think this particular combination could indeed be very differentiating from other combinations that others are pursuing, for example, what is already out there, TL1A alpha4beta7 or TL1A IL-23.

We thought rather than following these paths that others have already taken, we are exploring a novel combination here with a difficult-to-drug target at least historically and thereby potentially really have a very differentiated and potentially highly efficacious bispecific antibody in our hands.

Li Chen: Got it. Thanks for the color. And if I may, a quick follow-up. So, for example, when should we expect to see some go/no-go decision about prioritizing the monomeric TL1A versus the bispecific?

Sean McClain: So at this point in time, we are planning on pursuing both of these assets. And in terms of partners, partners are both interested in the TL1A monotherapy, as well as the bispecific. And so we, again, continue to develop both of these in parallel and see value in both of those. And I think it’s important to have both of these from a partnering perspective as well.

Li Chen: Okay. Thanks for taking the questions.

Operator: Thank you. That does end our Q&A session and concludes today’s conference call. Thank you for participating. You may now disconnect.